Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome.

Staedtke V, Bai RY, Kim K, Darvas M, Davila ML, Riggins GJ, Rothman PB, Papadopoulos N, Kinzler KW, Vogelstein B, Zhou S.

Nature. 2018 Dec;564(7735):273-277. doi: 10.1038/s41586-018-0774-y. Epub 2018 Dec 12.

PMID:
30542164
2.

Endothelial cells are able to synthesize and release catecholamines both in vitro and in vivo.

Sorriento D, Santulli G, Del Giudice C, Anastasio A, Trimarco B, Iaccarino G.

Hypertension. 2012 Jul;60(1):129-36. doi: 10.1161/HYPERTENSIONAHA.111.189605. Epub 2012 Jun 4.

PMID:
22665130
3.

Regulation of catecholamine release and tyrosine hydroxylase in human adrenal chromaffin cells by interleukin-1beta: role of neuropeptide Y and nitric oxide.

Rosmaninho-Salgado J, Araújo IM, Alvaro AR, Mendes AF, Ferreira L, Grouzmann E, Mota A, Duarte EP, Cavadas C.

J Neurochem. 2009 May;109(3):911-22. doi: 10.1111/j.1471-4159.2009.06023.x. Epub 2009 Mar 2.

4.

A Catecholamine Loop Mediates Cytokine Release Syndrome.

[No authors listed]

Cancer Discov. 2019 Feb;9(2):OF5. doi: 10.1158/2159-8290.CD-RW2019-002. Epub 2019 Jan 4.

PMID:
30610003
5.

Role of atrial natriuretic peptide on calcium channel mechanisms involved in catecholamine release from bovine adrenal medulla.

Fernandez BE, Dominguez AE, Gonzalez MA, Okobori R.

Arch Int Pharmacodyn Ther. 1992 Mar-Apr;316:105-13.

PMID:
1326931
6.

FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome.

Le RQ, Li L, Yuan W, Shord SS, Nie L, Habtemariam BA, Przepiorka D, Farrell AT, Pazdur R.

Oncologist. 2018 Aug;23(8):943-947. doi: 10.1634/theoncologist.2018-0028. Epub 2018 Apr 5.

7.

Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells.

Norelli M, Camisa B, Barbiera G, Falcone L, Purevdorj A, Genua M, Sanvito F, Ponzoni M, Doglioni C, Cristofori P, Traversari C, Bordignon C, Ciceri F, Ostuni R, Bonini C, Casucci M, Bondanza A.

Nat Med. 2018 Jun;24(6):739-748. doi: 10.1038/s41591-018-0036-4. Epub 2018 May 28.

PMID:
29808007
8.

Myeloid adrenergic signaling via CaMKII forms a feedforward loop of catecholamine biosynthesis.

Luo Y, Liu B, Yang X, Ma X, Zhang X, Bragin DE, Yang XO, Huang W, Liu M.

J Mol Cell Biol. 2017 Oct 1;9(5):422-434. doi: 10.1093/jmcb/mjx046.

9.

Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia.

Frey NV, Porter DL.

Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):567-572. Review.

10.

Cytokine release syndrome: grading, modeling, and new therapy.

Liu D, Zhao J.

J Hematol Oncol. 2018 Sep 24;11(1):121. doi: 10.1186/s13045-018-0653-x. Review.

11.

Catecholamines in patients with 22q11.2 deletion syndrome and the low-activity COMT polymorphism.

Graf WD, Unis AS, Yates CM, Sulzbacher S, Dinulos MB, Jack RM, Dugaw KA, Paddock MN, Parson WW.

Neurology. 2001 Aug 14;57(3):410-6.

PMID:
11502905
12.

Cytokine release syndrome in cancer immunotherapy with chimeric antigen receptor engineered T cells.

Xu XJ, Tang YM.

Cancer Lett. 2014 Feb 28;343(2):172-8. doi: 10.1016/j.canlet.2013.10.004. Epub 2013 Oct 16. Review.

PMID:
24141191
13.

Tocilizumab for severe cytokine-release syndrome after haploidentical donor transplantation in a patient with refractory Epstein-Barr virus-positive diffuse large B-cell lymphoma.

Ureshino H, Ando T, Kizuka H, Kusaba K, Sano H, Nishioka A, Itamura H, Shindo T, Kubota Y, Kojima K, Kimura S.

Hematol Oncol. 2018 Feb;36(1):324-327. doi: 10.1002/hon.2481. Epub 2017 Oct 3.

PMID:
28971493
14.

Atrial natriuretic peptide inhibits evoked catecholamine release by altering sensitivity to calcium.

Kanwal S, Elmquist BJ, Trachte GJ.

J Pharmacol Exp Ther. 1997 Nov;283(2):426-33.

PMID:
9353354
15.

Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel.

Porter D, Frey N, Wood PA, Weng Y, Grupp SA.

J Hematol Oncol. 2018 Mar 2;11(1):35. doi: 10.1186/s13045-018-0571-y. Review. Erratum in: J Hematol Oncol. 2018 Jun 13;11(1):81.

17.

C-type natriuretic peptide stimulates catecholamine synthesis through the accumulation of cyclic GMP in cultured bovine adrenal medullary cells.

Tsutsui M, Yanagihara N, Minami K, Kobayashi H, Nakashima Y, Kuroiwa A, Izumi F.

J Pharmacol Exp Ther. 1994 Feb;268(2):584-9.

PMID:
7906732
18.

Effects of natriuretic peptides (ANP, BNP, CNP) on catecholamine synthesis and TH mRNA levels in PC12 cells.

Takekoshi K, Ishii K, Isobe K, Nomura F, Nammoku T, Nakai T.

Life Sci. 2000 Apr 21;66(22):PL303-11.

PMID:
10834306
19.

Effect of atrial natriuretic peptide on catecholamine release from human pheochromocytoma.

Nakamaru M, Ogihara T, Saito H, Rakugi H, Hashizume K, Yamatodani A, Wada H, Kumahara Y.

Acta Endocrinol (Copenh). 1989 Jan;120(1):107-12.

PMID:
2521413
20.

Urocortin 2 lowers blood pressure and reduces plasma catecholamine levels in mice with hyperadrenergic activity.

Gu Y, Zhang K, Biswas N, Friese RS, Lin DH, Mahata SK, Hoshijima M, O'Connor DT, Peterson KL, Brar BK.

Endocrinology. 2010 Oct;151(10):4820-9. doi: 10.1210/en.2009-1454. Epub 2010 Jul 28.

Supplemental Content

Support Center